Novo Nordisk, a Danish pharmaceutical company, has partnered with South African drug manufacturer Aspen to produce insulin in vials for 1.1 million people in Africa by 2026. While the deal addresses insulin shortages, it doesn’t solve a key issue: South African public hospitals are running out of insulin pens, a more user-friendly option because Novo Nordisk stopped supplying them due…